Recent Quotes (30 days)

You have no recent quotes
chg | %

Kalytera Therapeutics Inc  

(Public, CVE:KALY)   Watch this stock  
Find more results for CVE:SMQ
-0.005 (-1.39%)
Apr 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.34 - 0.37
52 week 0.32 - 1.60
Open 0.37
Vol / Avg. 418,673.00/438,971.00
Mkt cap 44.03M
P/E     -
Div/yield     -
EPS -0.08
Shares 125.74M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -82050.00%
Operating margin - -82041.66%
EBITD margin - -76325.00%
Return on average assets -764.15% -290.53%
Return on average equity - -
CDP Score - -


The Exchange Tower 130 King St W Suite 2210
+1-416-3624441 (Phone)
+1-403-2668647 (Fax)


Kalytera Therapeutics Inc, formerly Santa Maria Petroleum Inc. is a Canada-based company, engaged in the development of cannabinoid (CBD) therapeutics. The Company is developing CBD formulations and prodrugs to target specific disease sites within the body. The Company's development programs include Bone Fracture Healing, Osteogenesis Imperfecta, Osteoporosis and Osteoporosis in Prader-Willi syndrome (PWS). The Company is focused on the development of KAL436/9, which is a synthetic derivative of CBD that has been structurally modified to develop solubility in water to improve potency. Its KAL671 is a synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis. The Company's researchers are exploring the ability for KAL671 to prevent bone loss in mice with genetic mutations designed to mimic aspects of PWS.

Officers and directors

Andrew A. DeFrancesco Chairman of the Board, President, Chief Executive Officer
Age: 45
Mike Dai Chief Financial Officer, Director
Pini Ben-Elazar Director
Michael Galloro Director
Scott R. Cochlan Independent Director
Douglas G. Manner Independent Director
Age: 56
Steven R. VanSickle Independent Director